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Abstract
Incretin-based therapies include pharmacologic agents such as glucagon like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors which exert potent anti-hyperglycemic
effects in the diabetic milieu. They are also shown to have extra-pancreatic effects.
Renin-angiotensin system is part of the endocrine system which is widely distributed in the
body and is closely involved in water and electrolyte homeostasis as well as renal and
cardiovascular functions. Hence the renin-angiotensin system is the main target for treating
patients with various renal and cardiovascular disorders. There is growing evidence that
incretins have modulatory effects on renin-angiotensin system activity; thereby, can be
promising therapeutic agents for the management of renal and cardiovascular disorders. But
the exact molecular interactions between incretins and renin-angiotensin system are not
clearly understood. In this current study, we have reviewed the possible molecular
mechanisms by which incretins modulate renin-angiotensin system activity.
Keywords: incretin, glucagon like peptide-1 receptor agonists, dipeptidyl peptdase-4
inhibitors, renin-angiotensin system, Na + /H + exchanger isotope 3.
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Introduction
Renin-angiotensin system (RAS) is a key player in salt and fluid homeostasis in the body and
so is closely associated with renal and cardiovascular physiology (Schmieder et al. , 2007).
RAS closely regulates hemodynamic states and promptly react to any changes in osmotic
pressure and blood volume (Schmieder et al., 2007). RAS is a key component in regulating
steady-state of hemodynamic status by modulating water and electrolyte balance (Schmieder
et al., 2007). Any defect in RAS will lead to the development of cardiovascular and renal
pathologies (Fyhrquist and Saijonmaa, 2008, Schmieder et al., 2007). Hence modulating the
activity of RAS is the main target for normalizing renal and cardiovascular functions in
various conditions including diabetes (Fyhrquist and Saijonmaa, 2008). Therefore,
antidiabetic agents which can modulate RAS activity could provide further therapeutic effects
more than reducing hyperglycemia (Kong et al. , 2014).
Incretin-based therapies are commonly used in patients with type 2 diabetes to lower blood
and is developed based on the hypoglycemic effects of incretin hormones (Lovshin and
Drucker, 2009). Incretins are a group of intestinal peptides which reduces postprandial
glucose by several mechanisms (Koliaki and Doupis, 2011, Lovshin and Drucker, 2009). Two
main class of antidiabetic drugs are available based on incretin physiology (Lovshin and
Drucker, 2009). These agents have potent hypoglycemic effects (Lovshin and Drucker, 2009,
Ussher and Drucker, 2014). However, there is growing evidence on the extrapancreatic
effects of these drugs including renoprotective effects (Koliaki and Doupis, 2011, Lovshin
and Zinman, 2014, Tonneijck et al. , 2014). This could potentially provide further beneficial
effects, such as lowering blood pressure and improving renal function (Baretić et al. , 2018).
In the current study, we reviewed the potential RAS modulatory effects of incretin-based
medications with a focus on promising renoprotective potentials.
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Incretin based therapies are used mainly in type 2 diabetes which is the most common type of
diabetes and is associated with insulin resistance in the peripheral tissue (Association, 2014).
The other main forms of diabetes are type 1 diabetes, gestational diabetes, maturity-onset
diabetes of the young, latent autoimmune diabetes of the adults and secondary diabetes due to
pancreatitis and medications such as steroids (Association, 2014, de Faria Maraschin, 2013,
O’Neal et al. , 2016).
Renin-Angiotensin System; roles in renal disorders
Renin-angiotensin system (RAS) or renin–angiotensin–aldosterone system (RAAS) is a
crucial hormonal system responsible for water and electrolytes homeostasis as well as
systemic vascular resistance (Boulpaep et al. , 2009). This system is triggered by releasing
the renin from the kidneys, mainly in response to hypovolemia or hyponatremia (Boulpaep et
al., 2009). Renin is synthesized from its precursor prorenin and stored in the renal
juxtaglomerular cells (Fountain and Lappin, 2019). Renin then cleaves angiotensinogen
(produced by the liver) into angiotensin I (AngI), which is subsequently converted to
angiotensin II (AngII) by the angiotensin-converting enzyme (ACE) predominantly on the
surface of vascular endothelial cells of the lungs as well as proximal renal tubules (Fountain
and Lappin, 2019). Ang II is a potent vasoconstrictive peptide that increases peripheral
vascular resistance and blood pressure (Fountain and Lappin, 2019). This system is highly
sensitive to any changes in plasma concentration, blood pressure and blood volume, and
reacts to these changes promptly (Khanna et al. , 2017). Ang II primarily acts as a very strong
vasoconstrictor (Khanna et al., 2017). This hormone acts by binding with type 1 (AT1) and
type 2 (AT2) receptors (Okuyama et al. , 1999). Also, it stimulates the release of aldosterone
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from the adrenal gland (zona glomerulosa) which regulates the homeostasis of mainly sodium
and potassium in the body (McCormick and Bradshaw, 2006).
RAAS has an important role in renal function by regulating fluid and electrolyte homeostasis
(Fountain and Lappin, 2019). Since the kidney has all elements involved in the RAS (or
RAAS), it has its specific system known as "intrarenal RAS" (Siragy and Carey, 2010).
Intrarenal RAAS not only regulates glomerular hemodynamics and tubular sodium transport
but also activates a number of inflammatory, oxidative and fibrotic processes involved in the
development of diabetic and non-diabetic nephropathies (Siragy and Carey, 2010). It has been
well confirmed that abnormal RAS activity is involved in the development of various renal
disorders (Balamuthusamy et al. , 2008, Molitch et al. , 2015, Nangaku and Fujita, 2008).
Both Ang II and aldosterone can initiate and worsen various pathophysiologic pathways such
as inflammation, oxidative stress, apoptosis and fibrosis (Siragy and Carey, 2010, Urushihara
and Kagami, 2017). It has been demonstrated that RAAS inhibitors can reduce albuminuria
and improve renal efficiency (Parving et al. , 2012). Activation of intrarenal RAAS is the
main feature of diabetic kidney diseases (Thomas, 2017). Also, patients with diabetic renal
failure usually have higher activities of mineralocorticoid receptors that are probably driven
by increased levels of circulating aldosterone due to higher RAAS activity (Messaoudi et al. ,
2012). Therefore, many pharmacological agents targeting this system were developed for
improving renal function through modulating RAAS activities (Fountain and Lappin, 2019).
Inhibitors of ACE, agents blocking Ang II receptors and direct renin inhibitors are three
known classes of medications targeting RAS activities that are widely used in patients with
renal and cardiovascular diseases (Fountain and Lappin, 2019).
Incretin-based antidiabetic medications
Incretins are a group of intestinal metabolic hormones such as glucagon like peptide-1
(GLP-1) and gastric inhibitory peptide (GIP), which decline postprandial glycaemia through
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several metabolic pathways such as inhibition of glucagon release, stimulation of insulin
secretion, delaying gastric emptying, suppression of appetite, diminishing intestinal
absorption of nutrients, improving lipid metabolism and promoting functions of pancreatic
β-cells (Baggio and Drucker, 2007, Ding et al. , 2006, Drucker and Nauck, 2006, Meier,
2012, Scott and Moran, 2007). The two main classes of antidiabetic agents developed based
on incretin physiology are GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4
inhibitors (DPP-4i) (Table 1) (Drucker and Nauck, 2006, Islam, 2016).
GLP-1RA is a group of medications used in the management of type 2 diabetes that provide
glucose-lowering effects by stimulation of GLP-1 receptors and thereby mimicking the
hypoglycemic effects of incretin hormones (Drucker and Nauck, 2006, Islam, 2016). These
medications bind to GLP-1 receptors on the surface of pancreatic β-cells. This GLP-1
receptor is a member of G-protein coupled receptors and its activation followed by generation
of cyclic adenosine monophosphate (cAMP) and cellular depolarization leads to insulin
secretion (Baggio and Drucker, 2007, Wootten et al. , 2011). GLP-1 is naturally metabolized
by a protease known as dipeptidyl peptidase-4 (DPP-4) (Association, 2018). This enzyme is
primarily a serine exopeptidase peptide cleaving X-proline or X-alanine dipeptides from the
N-terminus of targeted polypeptides including GLP-1 thereby deactivating them (Baetta and
Corsini, 2011). Inhibition of DPP-4 activity results in more physiologic effects of its
substrates including GLP-1 (Baetta and Corsini, 2011). Therefore, DPP-4 inhibitors (DPP4-i)
can reduce blood glucose by increasing the active circulatory levels of GLP-1 (Ahren, 2007,
Association, 2018). GLP-1RA and DPP-4i have some differences such as the effect on body
weight, degree of improvement in glycemic control and their adverse effect profile
(Association, 2018).
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Table 1: incretin-based antidiabetic drugs
Incretin-based therapies and Renin-Angiotensin System
Incretin-based therapies are effective in improving glycemia in patients with type 2 diabetes
(Drucker and Nauck, 2006, Islam, 2016). However, they also have some extrapancreatic
effects such as RAAS modulation and renoprotective effects (Muskiet et al. , 2014, Pyke et
al. , 2014). There is growing evidence that GLP-1 interacts with RAAS activities, decline Na
reabsorption in the proximal tubule and can modulate renal hemodynamics (Skov et al. ,
2013). These observations suggest that incretins-based therapies and RAS blockades have
synergistic effects in combination and so, not recommended to use together (Molitch et al.,
2015). In the following sections, we discuss the possible interactions between incretin-based
therapies and RAAS, which may provide promising renoprotective effects, especially in the
diabetic milieu.
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Fig 1; Molecular mechanisms by which incretins modulate RAAS activity (RAAS=
renin–angiotensin–aldosterone system, CNS=central nervous system, AT=angiotensin
receptor)
1. Direct Ang II inhibition
GLP based therapies can attenuate RAAS activity by decreasing Ang II expression and
activity (Baretić et al., 2018, Beraldo et al. , 2019, Kawase et al. , 2016). Beraldo et al. in
2019 found that 8 week treatment with sitagliptin down-regulated Ang II while increased
Ang 1-7 in cardiac tissues of nephrectomized rats (Beraldo et al., 2019). Koibuchi et al. in
2014 found that linagliptin (DPP-4i) down-regulated Ang II in cardiac tissues (Koibuchi et al.
, 2014). Also, Mima et al. in 2012 provided evidence showing that GLP-1 receptor signaling
attenuated Ang II signaling by a PKC dependent mechanism in glomerular endothelial cells
of diabetic mice overexpressing PKC (Mima et al. , 2012). Moreover, Baretic et al. in 2018
conducted a clinical study demonstrating GLP-1 infusion suppressed Ang II circulating level
in healthy participants (Baretić et al., 2018). The key finding of these studies was that GLP-1
interfere with Ang II secretion. But the exact molecular interactions are not fully understood.
Current knowledge suggests that GLP-1 can inhibit Ang II actions via PKA1 dependent
phosphorylation, direct effects of GLP-1 on renal juxtaglomerular cells, damping the
tubuloglomerular feedback by inhibition of proximal sodium transport and direct Ang II
down-regulation (Baretić et al., 2018, Koibuchi et al., 2014, Mima et al., 2012, Sedman et al.
, 2017). However, more studies are still required to confirm these effects.
2. Modulation of Na + /H + exchanger isotope 3 Activity
Na + /H + exchanger isotope 3 (NHE3) is a protein located in the brush border and apical
membrane of intestinal cells as well as proximal renal tubules (Tamura et al. , 2018, Yip and
Tse, 2014). This protein is mainly responsible for sodium and water balance and acid-base
1 Protein kinase A
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homeostasis via exchanging sodium with hydrogen ions and regulating the osmotic pressure
and diuresis (Tamura et al., 2018, Yip and Tse, 2014). Experimental evidence demonstrates
that NHE3 activity is involved in the effects of Ang II via AT1 receptor activation (Du
Cheyron et al. , 2003, Riquier-Brison et al. , 2010, Tamura et al., 2018). It has been shown
that Ang II induces NHE3 activity via promoting its localization on the cellular membrane
(Du Cheyron et al., 2003).
There is growing evidence that GLP-1 inhibits NHE3 protein and its activities (Crajoinas et
al. , 2016, Du Cheyron et al., 2003, Skov, 2014). They found that GLP-1 receptor induction
via either GLP-1RA and DPP-4i inhibits NHE3 trafficking and reduce its downstream effects
(Crajoinas et al., 2016, Girardi et al. , 2008). There is also some evidence that GLP-1 could
directly downregulate NHE3 protein (Crajoinas et al. , 2011). This suggests the GLP-1 has a
role in hypertensive disorders and sodium retention (Crajoinas et al., 2011). While the effects
of Ang II is dependent on NHE3 activity, these inhibitory effects of GLP-1 on NHE3 may be
the other possible link by which GLP-1 modulates Ang II activities (Carraro-Lacroix et al. ,
2009, Crajoinas et al., 2016, Kim et al. , 2013, Skov, 2014, Skov et al., 2013). Therefore, the
natriuretic effects of Ang II is under the influence of GLP-1, which can modulate NHE3
activity (Carraro-Lacroix et al., 2009, Girardi et al. , 2004, Kim et al., 2013). However, the
exact mechanism by which GLP-1 modulate NHE3 activities is not well understood.
3. Modulation of upstream RAAS-induced pathophysiology
RAAS activity is under the influence of various pathophysiologic pathways such as oxidative
stress and inflammation (Husain et al. , 2015, Touyz, 2004, Virdis et al. , 2011). It has been
shown that oxidative stress and inflammation promote RAAS activation in several ways and
thereby induce its downstream effects (Husain et al., 2015, VAZIRI, 2008). Therefore, one
can hypothesize that modulation of these deleterious pathways could modulate RAAS
activation indirectly. There is evidence implying that GLP-1 exerts antioxidant and
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anti-inflammatory effects (Alam et al. , 2015, Li et al. , 2016, Yaribeygi et al. , 2020). These
effects of GLP-1 based therapies could be another link between these agents and RAAS
activation (Skov, 2014) which needs further evaluation.
4. Modulation of CNS-Induced RAAS Activation
The central nervous system (CNS) has a regulatory role in RAAS activity (Choi et al. , 2011,
Tsuda, 2012, Von Bohlen und Halbach and Albrecht, 2006). It has been well confirmed that
the CNS has its own RAS with all its related components and receptors such as AT1 and AT2
(Choi et al., 2011). This system is expressed in most area of CNS and produce bioactive
compounds such as Ang 1–7, Ang II, Ang IV and Ang 1-8 (Nakagawa et al. , 2020). CNS
dependent RAAS is involved not only in the hemodynamic processes and regulation of BP,
but also in many biological and neurobiological activities as processing sensory information,
learning, memory, and emotional responses (Nakagawa et al., 2020).
There is some evidence suggesting that incretins have modulatory effects of CNS-dependent
RAAS activities, although this complex relationship has not fully understood yet (Zhang et
al. , 2019). Beside GLP-1, DPP-4i cleaves several biologic peptides such as substance P,
which are released from the ends of primary afferent sensory nerve fibers producing
vasodilatory and sympathomimetic effects (Tonneijck et al., 2014, Wilson et al. , 2019). It is
also responsible for cleaving neuropeptide Y (NPY) which is a metabolic neurotransmitter in
the sympathetic nervous system (Tonneijck et al., 2014). Both of these two peptides
(substance P and NPY) have modulatory effects on RAAS activity and when incretins-based
therapies are combined with ACE inhibitors, these effects will be exaggerated (Devin et al. ,
2014, Molitch et al., 2015, Tonneijck et al., 2014). Therefore, DPP-4i has been suggested as
having antihypertensive potential by negatively modulating the RAAS activities (Zhang et
al., 2019). Stromal-cell-derived factor-1 (SDF-1) and natriuretic peptide B (BNP) are other
main substrates of DPP-4i which have modulatory effects of CNS as well as RAAS (Zhang et
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al., 2019). However, some studies revealed that high doses of ACE inhibitors in combination
with DPP-4i increases BP (Jackson et al. , 2015, Marney et al. , 2010). Hence, more studies
are required to confirm these effects.
5. Modulating the expression of AT1/AT2 receptors
AT1 causes contraction of the smooth muscle resulting in sodium and water retention leading
to increased systemic vascular resistance and an increase in blood pressure. However, AT2
stimulation has opposite effects and can act as an antagonist to AT1 (Kawase et al., 2016).
Hence the balance of AT1/AT2 expression determines the RAAS activity (Kaschina and
Unger, 2003, Kawase et al., 2016). Some recent evidence suggests that incretins alter this
relation toward more AT2 expression (Kawase et al., 2016). For example, Zhang et al. in
2015 demonstrated that liraglutide improved cardiac remodeling via altering AT1/AT2 level
in cardiomyocytes of hypertensive rats (Zhang et al. , 2015). Also, Bai and colleagues in
2020 demonstrated that liraglutide and linagliptin reduced AT1/AT2 ratio in the glomerular
capillaries and proximal tubules of the renal cortex of rats (Bai et al. , 2020). They suggested
that incretins prevented the renal fibrosis via lowering the RAAS activity by altering
AT1/AT2 ratio (Bai et al., 2020). This suggests that altering the AT1/AT2 ratio could be one
of the pathways by which incretins affects the activity of RAAS.
Molecular Pathways Effects Ref.
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Table 2; Possible molecular mechanisms by which GLP-1RA and/or DPP-4i modulate
RAAS activity
Clinical Evidence
Some clinical studies have confirmed the RAAS-modulatory effects of incretins in human
(Baretić et al., 2018, Gutzwiller et al. , 2004, Skov et al., 2013). For instance, Baretic et al. in
2018 found that GLP-1 infusion significantly altered RAAS activity and reduced aldosterone
release in healthy subjects (Baretić et al., 2018). Also, Skove and coworkers in 2013
conducted a clinical study demonstrating GLP-1 infusion reduced Ang II secretion and
related activities in healthy participants (Skov et al., 2013). Other main related clinical studies
are presented in table 3.



























































Table 3; Clinical studies on the RAS modulatory effects of GLP-1RA and DPP-4i
Conclusion
Renin-angiotensin system dysfunction is involved in the pathophysiology of various
cardiovascular and renal disorders and thereby, RAS modulatory pharmacologic agents are
commonly used to manage patients with these disorders. Incretins based pharmacological
agents including GLP-1 receptor agonists and DPP-4 inhibitors, are commonly used in
patients with type 2 diabetes but has shown to have some extra-pancreatic effects. In the
current study, we conclude that incretins can potentially modulate RAS activity via at least
five molecular pathways. This suggests that incretins-based medications are promising agents
for managing patients with cardiovascular and renal disorders which need to be confirmed in
clinical studies.
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